프라더 윌리 증후군(PWS) : 신규 요법, 미충족 수요 및 TPP 인사이트 리포트(2026년)

Prader-Willi Syndrome (PWS) Emerging Therapy and TPP Insights

Thelansis's "Prader-Willi Syndrome (PWS) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Prader-Willi Syndrome (PWS) Overview

arises from a paternal deletion or maternal uniparental disomy, leading to profound hypothalamic dysfunction-the central driver of the disease phenotype.

Clinically, PWS follows a well-defined biphasic trajectory. The neonatal phase is marked by severe central hypotonia, poor feeding, and failure to thrive. This transitions in early childhood to pathologic hyperphagia, characterized by impaired satiety signaling and relentless food-seeking behavior. Without strict intervention, this results in rapid-onset obesity and downstream metabolic complications, including Type 2 Diabetes and severe Obstructive Sleep Apnea.

Beyond metabolic burden, PWS presents with a broad neurobehavioral and endocrine spectrum, including mild-to-moderate intellectual disability, compulsive behaviors, emotional dysregulation, hypogonadism, and central growth hormone deficiency. Management remains highly resource-intensive and multidisciplinary. Early initiation of recombinant human growth hormone (rhGH) therapy is the cornerstone of care, demonstrating benefits in linear growth, body composition, and metabolic parameters. However, there are no approved therapies targeting hyperphagia, which remains the most critical unmet need. As a result, long-term disease control depends heavily on stringent environmental measures (e.g., food security restrictions) and continuous caregiver supervision.

Key Highlights:

• PWS is a rare, lifelong, multisystem disorder driven by hypothalamic dysfunction, with a stable but gradually increasing diagnosed patient population in the US.
• The US prevalent population is estimated to grow from 13.9K in 2025 to 14.8K by 2035, reflecting a modest growth trajectory (0.6-0.7% CAGR) driven by improved diagnosis and survival.
• The disease is characterized by severe hyperphagia and obesity-related complications, representing the most critical unmet need due to the absence of approved targeted therapies.
• Increasing clinical focus on appetite-regulating and hypothalamic pathway-targeted therapies is expected to significantly transform the future treatment landscape.

Market Overview:

• The US PWS market is projected to expand from $559M in 2025 to $3.96B by 2035, reflecting a strong double-digit CAGR, primarily driven by late-stage pipeline therapies targeting hyperphagia.
• Current market revenues are largely supported by recombinant human growth hormone (rhGH) therapy, which addresses growth and metabolic aspects but not hyperphagia.
• Future market expansion will be highly dependent on successful commercialization of therapies targeting appetite dysregulation and improving long-term disease outcomes.

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Harmony Biosciences Management, Inc.
• ConSynance Therapeutics
• Soleno Therapeutics, Inc.
• Bright Minds Biosciences Pty Ltd
• Aardvark Therapeutics, Inc.
• Pfizer
• Rhythm Pharmaceuticals, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)